RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi therapeutics market with its strong technology platform, broad intellectual property position, a management team that is experienced in commercializing products,… More
RXi is a recent spinoff of the RNA interference division of the small cap biotech CytRx. For the past couple of years CytRx has only been notable for the successive failures of its small molecule chaperone technology. In fact, at this time CytRx's… More